Urothelial Cancer Symptoms, Doctors, Treatments, Advances & More

Learn About Urothelial Cancer

What is the definition of Urothelial Cancer?

Urothelial cancer, also known as transitional cell carcinoma, affects the kidney (renal) pelvis or ureter (tube) that drains urine from the kidney to the bladder and/or the lining of the inside of the bladder. It is the most common form of bladder cancer and occurs more frequently in men and older adults. The cause of urothelial cancer is unknown; however, some suspected causes are chronic irritation of the kidney from pain medicines, exposure to manufacturing chemicals and dyes, smoking or other tobacco use, past radiation exposure, and parasitic infections.

Save information for later

What are the symptoms of Urothelial Cancer?

Symptoms of urothelial cancer include fatigue, unexplained weight loss, loss of appetite, anemia, constant back pain, flank pain, pelvic pain, urinary urgency, pain, burning, or discomfort when urinating, or blood in urine (hematuria).

Not sure about your diagnosis?

Check Your Symptoms

What are the current treatments for Urothelial Cancer?

Treatment for urothelial cancer includes surgery and chemotherapy. Bladder cancer can recur after treatment; therefore, long-term follow-up is necessary.

Who are the top Urothelial Cancer Local Doctors?

Dr. Guido M. Dalbagni

Urology

Elite

Highly rated in

conditions

Urology

Memorial Sloan Kettering Bergen

225 Summit Ave,

Montvale, NJ

Guido Dalbagni is an Urologist in Montvale, New Jersey. Dalbagni has been practicing medicine for over 44 years and is rated as an Elite expert by MediFind in the treatment of Urothelial Cancer. He is also highly rated in 19 other conditions, according to our data. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Endoscopy. Dalbagni is currently accepting new patients.

Dr. Sumanta K. Pal

Oncology

Elite

Highly rated in

conditions

Oncology

City of Hope

City Of Hope Medical Foundation

1601 Avocado Ave,

Newport Beach, CA

Sumanta Pal is an Oncologist in Newport Beach, California. Pal has been practicing medicine for over 20 years and is rated as an Elite expert by MediFind in the treatment of Urothelial Cancer. He is also highly rated in 25 other conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Prostatectomy, and Orchiectomy.

Learn about our expert tiers

Learn more

Dr. Ashish M. Kamat

Urology

Elite

Highly rated in

conditions

Urology

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd,

Houston, TX

Ashish Kamat is an Urologist in Houston, Texas. Kamat has been practicing medicine for over 29 years and is rated as an Elite expert by MediFind in the treatment of Urothelial Cancer. He is also highly rated in 9 other conditions, according to our data. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Endoscopy. Kamat is currently accepting new patients.

View All Doctors

What are the latest Urothelial Cancer Clinical Trials?

A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma

Who is this study for: Adult patients with advanced solid tumors

Enrollment Status: Recruiting

Publish Date: February 15, 2023

Intervention Type: Drug

Study Drugs: CisplatinElimusertibGemcitabine HydrochlorideBAY 1895344

Study Phase: Phase 1

Summary: This phase I trial identifies the best dose, possible benefits and/or side effects of BAY 1895344 in combination with chemotherapy in treating patients with solid tumors or urothelial cancer that has spread to other places in the body (advanced). BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cisplatin and gemcitabine are chemotherapy drugs t...

Match to trials

Find the right clinical trials for you in under a minute

Get started

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.

Who is this study for: Adult patients with Unresectable, Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium that have not been treated with first-line chemotherapy but have received radiotherapy

Enrollment Status: Recruiting

Publish Date: February 15, 2023

Intervention Type: Drug

Study Drugs: DurvalumabTremelimumabCisplatinGemcitabineCarboplatin

Study Phase: Phase 3

Summary: This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documente...

View All Clinical Trials

What are the Latest Advances for Urothelial Cancer?